168897-19-6

Basic information

• Product Name: Pyrrolidine, 1-[2-(4-nitrophenyl)ethyl]-
• CAS NO: 168897-19-6
• Molecular Formula: C12H16N2O2
• Molecular Weight: 220.271
• Mol File: 168897-19-6.mol

Chemical Properties

• CAS DataBase Reference: Pyrrolidine, 1-[2-(4-nitrophenyl)ethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrrolidine, 1-[2-(4-nitrophenyl)ethyl]-(168897-19-6)
• EPA Substance Registry System: Pyrrolidine, 1-[2-(4-nitrophenyl)ethyl]-(168897-19-6)

Safety Data

• Hazardous Substances Data: 168897-19-6(Hazardous Substances Data)

Upstream product

• 123-75-1 pyrrolidine 
• 100-13-0 4-nitrostyrene 
• 5339-26-4 (4-nitrophenyl)ethyl bromide 
• 20020-28-4 <(p-Nitrophenyl)ethyl>-β-sulfonic ester 
• 20264-96-4 2-(4-nitrophenyl)ethyl iodide 
• 103-63-9 1-phenyl-2-bromoethane 
• 168897-62-9 2-(4-nitrophenyl)-1-(pyrrolidin-1-yl)ethan-1-one 
• 555-16-8 4-nitrobenzaldehdye 
• 51738-10-4 2,2-dibromo-1-(4-nitrophenyl)ethene 

Downstream Products

• 1567327-13-2 2-(4-(2-(pyrrolidin-1-yl)ethyl)phenyl)benzo[d][1,2]selenazol-3(2H)-one 
• 1567327-19-8 5,6-dimethoxy-2-(4-(2-(pyrrolidin-1-yl)ethyl)phenyl)benzo[d][1,2]selenazol-3(2H)-one 
• 168897-20-9 4-(2-pyrrolidin-1-yl-ethyl)phenylamine 

Relevant articles and documents

Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease

A series of ebselen derivatives were designed, synthesised and evaluated as inhibitors of cholinesterases (ChEs) and glutathione peroxidase (GPx) mimics. Most of the compounds were found to be potent against AChEs and BuChE, compounds 5e and 5i, proved to be the most potent against AChE with IC50 values of 0.76 and 0.46 μM, respectively. Among these hybrids, most of the compounds were found to be good GPx mimics compare with ebselen. The selected compounds 5e and 5i were also used to determine the catalytic parameters and in vitro hydrogen peroxide scavenging activity. The results indicate that compounds 5e and 5i may be excellent multifunctional agents for the treatment of AD.

8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.

Synthesis and biological evaluation of new 4β-anilino-4′-O- demethyl-4-desoxypodophyllotoxin derivatives as potential antitumor agents

A series of new 4β-anilino-4′-O-demethyl-4-desoxypodophyllotoxin derivatives were prepared and evaluated for their cytotoxicities against four human cancer cell lines including KB, KB/VCR, A549 and 95D. Most compounds showed better growth-inhibition activities against tested cell lines than that of etoposide (VP-16). Preliminary structure-activity relationships (SARs) were concluded and it indicated that the side chains substituted at 4β position of podophyllotoxin significantly influenced the cytotoxic activity, especially for the drug resistance profile. In vivo studies of compound 26c on highly metastatic human lung cancer xenograft in nude mice showed that it can significantly inhibit tumor growth with administrating by oral route.

IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION

Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. Formula (I).

In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: Trends across multiple chemical series

Structure-activity relationships (SAR) were analyzed within a library of diverse yet simple compounds prepared as histamine H3 antagonists. The libraries were constructed with a variety of low molecular weight pyrrolidines, selected from (R)-2-methylpyrrolidine, (S)-2-methylpyrrolidine, and pyrrolidine.

Thiazolidinones, their production and use as pharmaceutical agents

Thiazolidinones of general formula I in which Q, A, B, X, R1 and R2 have the meanings that are indicated in the description, as well as those of general formula IA in which Q, A, B, X, R1 and R2a have the meanings that are indicated in the description, their production and use as inhibitors of the polo-like kinase (PLK) for treating various diseases as well as intermediate products for the production of thiazolidinones are described.

1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.

Substituted indolines which inhibit receptor tyrosine kinases

Indolinones of the formula having an inhibitory effect on receptor tyrosine kinases and cyclin/CDK complexes, as well as on the proliferation of endothelial cells and various tumor cells. Exemplary are: (a) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (b) 3-Z-[(1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone, and (c) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-metboxycarbonyl-2-indolinone.